SARS-COV-2 Mpro conformational changes induced by covalently bound ligands

被引:0
|
作者
Ferreira, Glaucio Monteiro [1 ,2 ]
Kronenberger, Thales [2 ,3 ]
Tonduru, Arun Kumar [3 ]
Hirata, Rosario Dominguez Crespo [1 ]
Hirata, Mario Hiroyuki [1 ]
Poso, Antti [2 ,3 ]
机构
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil
[2] Univ Hosp Tubingen, Dept Oncol & Pneumonol, Internal Med 8, Tubingen, Germany
[3] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland
基金
巴西圣保罗研究基金会;
关键词
COVID-19; main protease; M-pro; Molecular dynamics simulation; PROTEIN; MOLECULES;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SARS-CoV-2's main protease (M-pro) interaction with ligands has been explored with a myriad of crystal structures, most of the monomers. Nonetheless, Mpro is known to be active as a dimer but the relevance of the dimerization in the ligand-induced conformational changes has not been fully elucidated. We systematically simulated different Mpro-ligand complexes aiming to study their conformational changes and interactions, through molecular dynamics (MD). We focused on covalently bound ligands (N1 and N3, similar to 9 ls per system both monomers and dimers) and compared these trajectories against the apostructure. Our results suggest that the monomeric simulations led to an unrealistically flexible active site. In contrast, the Mpro dimer displayed a stable oxyanion-loop conformation along the trajectory. Also, ligand interactions with residues His41, Gly143, His163, Glu166 and Gln189 are postulated to impact the ligands' inhibitory activity significantly. In dimeric simulations, especially Gly143 and His163 have increased interaction frequencies. In conclusion, long-timescale MD is a more suitable tool for exploring in silico the activity of bioactive compounds that potentially inhibit the dimeric form of SARS-CoV-2 Mpro.
引用
收藏
页码:12347 / 12357
页数:11
相关论文
共 50 条
  • [1] SARS-COV-2 Mpro conformational changes induced by covalently bound ligands
    Ferreira, Glaucio Monteiro
    Kronenberger, Thales
    Tonduru, Arun Kumar
    Crespo Hirata, Rosario Dominguez
    Hirata, Mario Hiroyuki
    Poso, Antti
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021,
  • [2] Advances in the Development of SARS-CoV-2 Mpro Inhibitors
    Agost-Beltran, Laura
    de la Hoz-Rodriguez, Sergio
    Bou-Iserte, Lledo
    Rodriguez, Santiago
    Fernandez-de-la-Pradilla, Adrian
    Gonzalez, Florenci V.
    MOLECULES, 2022, 27 (08):
  • [3] SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs
    Bharadwaj, Shiv
    Azhar, Esam Ibraheem
    Kamal, Mohammad Amjad
    Bajrai, Leena Hussein
    Dubey, Amit
    Jha, Kanupriya
    Yadava, Umesh
    Kang, Sang Gu
    Dwivedi, Vivek Dhar
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (06) : 2769 - 2784
  • [4] Unbinding ligands from SARS-CoV-2 Mpro via umbrella sampling simulations
    Nguyen Minh Tam
    Trung Hai Nguyen
    Vu Thi Ngan
    Nguyen Thanh Tung
    Son Tung Ngo
    ROYAL SOCIETY OPEN SCIENCE, 2022, 9 (01):
  • [5] Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro
    Papaj, Katarzyna
    Spychalska, Patrycja
    Hopko, Katarzyna
    Kapica, Patryk
    Fisher, Andre
    Lill, Markus A.
    Bagrowska, Weronika
    Nowak, Jakub
    Szleper, Katarzyna
    Smiesko, Martin
    Kasprzycka, Anna
    Gora, Artur
    PHARMACEUTICALS, 2021, 14 (11)
  • [6] Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS-CoV-2 Mpro
    Citarella, Andrea
    Moi, Davide
    Pedrini, Martina
    Perez-Pena, Helena
    Pieraccini, Stefano
    Stagno, Claudio
    Micale, Nicola
    Schirmeister, Tanja
    Sibille, Giulia
    Gribaudo, Giorgio
    Silvani, Alessandra
    Passarella, Daniele
    Giannini, Clelia
    MOLECULES, 2023, 28 (02):
  • [7] Development of novel ligands against SARS-CoV-2 Mpro enzyme: an in silico and in vitro Study
    Kaboudi, Navid
    Krueger, Nadine
    Hamzeh-Mivehroud, Maryam
    MOLECULAR INFORMATICS, 2023, 42 (11)
  • [8] SARS-CoV-2 Mpro oligomerization as a potential target for therapy
    Lis, Kinga
    Plewka, Jacek
    Menezes, Filipe
    Bielecka, Ewa
    Chykunova, Yuliya
    Pustelny, Katarzyna
    Niebling, Stephan
    Garcia, Angelica Struve
    Garcia-Alai, Maria
    Popowicz, Grzegorz M.
    Czarna, Anna
    Kantyka, Tomasz
    Pyrc, Krzysztof
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 267
  • [9] The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (Mpro)
    Ebrahim, Ali
    Riley, Blake T.
    Kumaran, Desigan
    Andi, Babak
    Fuchs, Martin R.
    McSweeney, Sean
    Keedy, Daniel A.
    IUCRJ, 2022, 9 : 682 - 694
  • [10] Structural biology of SARS-CoV-2 Mpro and drug discovery
    Duan, Yinkai
    Wang, Haofeng
    Yuan, Zhenghong
    Yang, Haitao
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2023, 82